Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 820 + Pembrolizumab in Advanced Solid Tumors
NCT02713529Phase 2Completed
- Sponsor
- AmMax Bio
- Start
- Apr 2016
- Primary completion
- Jan 2019
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 2 trial of AMG 820 in pancreatic cancer (PC), colorectal cancer (CRC), non-small cell lung cancer (NSCLC), sponsored by AmMax Bio. Started Apr 2016; status: completed.
02
Drugs
AMG 820
03
Conditions
pancreatic cancer (PC)colorectal cancer (CRC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02713529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02713529.